A satellite firm valued in private rounds is borrowing to bid for a listed rocket maker. Lenders that took over Neovia agreed to sell it to a KKR-owned buyer. The S&P 500 fell for a sixth straight day.

THE NUMBER

38%.

That is about the premium Palo Alto Networks (PANW) agreed to pay for an AI firm. It is measured against the firm's private round two weeks earlier. That round valued Applied Compute at $3.25 billion, according to reports. Palo Alto agreed to pay $4.5 billion, all in stock. Its shares rose 9.9% on Wednesday, before it announced the deal. They closed up about 6.4% on Thursday. The company had also beaten forecasts and raised its outlook.

A public buyer agreed to a higher price and will pay it in stock that had just risen.

PREMIER FEATURE

Lately Every Top Stock List Has Started Looking the Same.

Nothing wrong with Nvidia, Tesla, or SpaceX, but we believe there are plenty of other top-quality opportunities for investors willing to dig into the details.

That's why our MarketBeat analysts built an all-new list of the 5 Best Stocks to Buy Now.

Every company on the list:

  • Worth at least $5 billion
  • Strong fundamentals
  • Strong growth prospects ahead

You'll get the full bull case, and the full bear case, for each stock. Every opportunity, every risk, every factor we considered. So you can invest with confidence.

The report is called 5 Stocks to Buy Now, and it's yours free today.

Send My Free Report

THE SETUP
  • Anthropic (ANT) opened at $111.50 in its Nasdaq debut. That was 34% above its $83 IPO price. It closed at about $97, roughly 17% above the IPO price.
  • The S&P 500 closed down about 2%, its sixth straight loss. The Dow and the Nasdaq each fell about 2.2%. The 10-year yield ended near 5.05%.
  • A Philadelphia Fed factory gauge sank to 6.3 from 20.9. Its prices-paid reading jumped to 58.2. Kalshi traders still see a quarter-point hike in December as close to settled, near 92 cents. Bets on a bigger hike jumped to 9 cents after the Fed's minutes, then faded.
  • Walmart (WMT) beat sales forecasts and raised its outlook for a third time this year. The new range still came in below what analysts expected. The stock closed down about 1%.
IN FOCUS

Two Buyout Firms Agreed to Buy Into Brunt. The Reported Value Appears to Trail the Seller's Goal.

Permira and Freeman Spogli are buying control of Brunt Workwear. Brunt is a founder-led maker of boots and work clothes. The deal values it at more than $800 million, Reuters reported, citing three people familiar with the matter. Brunt confirmed the deal but gave no terms. Its founder will stay on as chief executive.

That appears to be below the target. A sale process earlier this year reportedly aimed for more than $1 billion. Brunt has about $300 million in yearly sales, per reports the company has not confirmed.

Much is still unknown. The split between the two firms, the debt and the closing date are not public. Nor is any stake the founder keeps. Splitting one equity check between two firms spreads the risk of owning a single brand.

Other buyers this week paid more freely. Applied Compute's price is about 38% over its last private round, paid in Palo Alto stock. ICEYE offered Avio holders a premium it puts at 21.3%, funded in part with debt. Brunt's buyers are spending fund money, with no rising stock to pay with.

A Deal Cleared, Apparently Under the Goal

For consumer-buyout investors, the reported value appears to fall short of what the seller wanted. If that gap holds, it is one sign that sponsors pay less for consumer growth than sellers expect. It may also mean the target was set too high. Terms at closing, or other brands selling near their targets, would show which read holds.

FROM OUR PARTNERS

Porter Stansberry's Critical New Warning:

Trump Is Replacing The U.S. Dollar

"The last time America reset its money, it created 1,300 millionaires every day. This could be bigger."

Get the full story — and the five stocks to own now

SIGNALS IN MOTION

SIGNAL 1: A Satellite Firm Valued in Private Rounds Is Borrowing to Bid for a Listed Rocket Maker.

ICEYE offered €41 a share in cash for Avio. ICEYE put that at 21.3% above the Nov. 16 price. It is a Finnish satellite firm backed by venture funds. It was valued at more than €10 billion in June. It would pay up to about €2.05 billion, using cash and new debt, and plans to delist Avio. It needs two-thirds of the shares, a bar it can waive.

Leonardo holds 18.04% of Avio, and Advent holds 6.54%. Italy's defense minister said that if he were Leonardo, he would think carefully before he sold. Rome must clear the deal under its golden-power rules. France, the U.K., the EU and the U.S. must approve it too. Avio closed at €39.60 on Thursday, about 3.4% below the offer.

WHAT RESOLVES THIS

For venture investors, a start-up their money built is now bidding for a listed company. That role usually falls to industry buyers or buyout firms. Its private value and borrowed money help make the premium possible. If Leonardo does not sell, ICEYE needs about 81% of the rest to reach two-thirds. Leonardo's choice and the Avio board's view will show whether €41 holds.

SIGNAL 2: Lenders That Took Over Neovia Agreed to Sell It to a KKR-Owned Buyer.

LOGISTEED signed a deal to buy Neovia Logistics. The sellers are funds run by Oaktree, Ares Management (ARES) and Vector Capital. LOGISTEED is owned by KKR (KKR). The sellers took control of Neovia in 2022, when they swapped their loans for equity. Terms were not disclosed.

The combined firm would have more than ¥1 trillion of sales. The deal is expected to close in the first quarter of 2027, pending approvals.

WHAT RESOLVES THIS

For private-credit investors, this is the loan-to-own route reaching a buyer. Lenders that never set out to run a logistics firm have agreed to sell to an owner backed by a buyout firm. Without a price, outsiders cannot judge what the lenders got back on their loans. A price or recovery figure in the sellers' fund reports would show whether the route paid off.

PARTNER SPOTLIGHT

Middle East Conflict Lights Fuse on US Debt Bomb

America was already drowning in $38 trillion of debt, but the recent conflict in the Middle East just accelerated the timeline.

As oil spikes, a 100-year-old stock market signal that accurately predicted the 2008 and 2020 crashes is flashing a massive "Sell" on dozens of popular U.S. equities.

If you hold the wrong stocks when this debt crisis hits, it could wipe out years of gains.

Click here to see the 10 popular stocks to dump immediately

11780 US Highway 1, Palm Beach Gardens, FL 33408-3080 Would you like to edit your e-mail notification preferences or unsubscribe from our mailing list? Copyright © 2026 Weiss Ratings. All rights reserved.

WHAT MOST WILL MISS
THE CROSSOVER

Private Market Trends Driving Public Market Moves

A Boot Brand Likely Cleared Below Its Ask. An AI Start-Up Drew a 38% Step-Up.

Private prices split this week, and the split tracked what buyers pay with. Brunt's buyers agreed to a value that appears to sit below the seller's goal. Palo Alto, paying in stock, agreed to a premium, and ICEYE, partly with debt, offered one. Public prices swung harder. Anthropic opened 34% above its IPO price. It gave back about half of that gain as the S&P 500 fell for a sixth day. Our read is that buyers with a rich currency pay up. For Palo Alto that is its stock, and for ICEYE a high private value plus debt. Buyers spending a fund's cash hold the line. Brunt's final terms, and how Palo Alto's stock trades before its deal closes, would test that read.

On the calendar...

When

Event

Fri., Nov. 20

Anthropic offering expected to close

Wed., Nov. 25

October PCE price index

Fri., Dec. 4

November jobs report

Wed., Dec. 9

Fed rate decision

First quarter 2027

Neovia sale expected to close

AI Found the Target. AI Designed the Drug. Now It's in Phase III.

For years, AI drug discovery had a problem. Plenty of models. Very few medicines.
That's changing. One company says AI identified the biological target and then designed the molecule to hit it. In September, the first patient in its Phase III trial was dosed.
It isn't alone. A second AI-engineered medicine is in Phase III, and Big Pharma is now paying for the technology.
We profiled the 5 companies pushing AI into real drug development in a new FREE Special Report: AI Moves Into the Biotech Lab.
We'll text it straight to your phone.

Get the Free Report by Text →